olean-11,13(18)-diene | 54411-26-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: olean-11,13(18)-diene
• 英文别名: oleana-11,13(18)-diene；Oleana-11,13(18)-dien；Oleanadien-(11.13(18))；Oleandien-(11.¹².13¹⁸)；(4aS,6aR,6bS,8aR,14aR,14bS)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicene
• CAS: 54411-26-6
• 化学式: C₃₀H₄₈
• 分子量: 408.711
• InChiKey: OOVSUFZRKGCLKQ-RBXQBWMISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.2
• 重原子数：
  30
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  olean-11,13(18)-diene 在 环己烷 、 溶剂黄146 、 铂 作用下， 生成 olean-13(18)-ene
  参考文献：
  名称：

  有关三萜的知识。第153部分。蒲公英赛醇转化为Δ 13,18 oleans

  摘要：

  蒲公英油是五环的单不饱和仲三萜醇。通过Clemmensen还原相应的酮类Tar草酮，Δ为13.18韩元-Oleanen。

  DOI：

  10.1002/hlca.19500330434
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 olean-11,13(18)-diene
  参考文献：
  名称：

  Long-term glycemic control measurements in diabetic patients receiving hemodialysis

  摘要：

  Cardiovascular morbidity is increased in patients with diabetes mellitus and there is a great prevalence of diabetes and cardiovascular disease among patients with end-stage renal disease (ESRD). Control of glycemia can decrease cardiovascular and end-organ damage. Because the validity of glycemic control tests have not been rigorously studied in patients with ESRD, we evaluated the value of various measures in these patients. The overall clinical goal was to investigate whether hemoglobin A(1)C (A(1)C) accurately reflects actual glycemic control as compared with other measures in light of the importance of attaining appropriately controlled blood glucose (BG). The commonly used tests of total glycated hemoglobin (GHb) and A(1)C may be unreliable in patients with ESRD because of the presence of anemia, shortened red blood cell (RBC) survival, and assay interferences from uremia. The primary aim of this study was to assess the relationship of capillary BG measurements to A(1)C, GHb, total glycated plasma proteins (GPP), and fructosamine (Fr) in diabetic patients receiving hemodialysis. Twenty-three patients were instructed to obtain BG evaluations twice daily for 7 days by using the Elite glucometer (Bayer Corporation, Elkhart, IN). These determinations included 6 fasting, 6 preprandial, and 3 separate 2-hour postprandial levels. Blood was obtained on day 7 for measurement of A(1)C, GHb, GPP, and Fr. A(1)C was analyzed by an immunoassay, GPP and GHb were assayed by affinity high-performance liquid chromatography (HPLC), and Fr by automated nitroblue colorimetric assay. Scatter plots were generated by plotting the average BG versus A(1)C, GHb, GPP, or Fr. Linear regression was performed for each plot showing the following relationships: A(1)C = 0.0174 (BG) + 4.76 (r = 0.58; P < 0.05): GHb = 0.0371 (BG) + 3.57 (r = 0.584; P < 0.05): GPP = 0.0083 (BG) + 26.13 (r = 0.065; P = 0.77): Fr = 0.6865 (BG) + 250 (r = 0.345; P = 0.11). Despite anemia and shortened RBC lifespan in patients with ESRD, A(1)C in the range of 6% to 7% estimates glycemic control similarly to patients without severe renal impairment. A(1)C values above 7.5% may overestimate hyperglycemia in patients with ESRD. Thus, diabetic patients receiving hemodialysis may have long-term BG that are more properly controlled than previously determined, reducing their risks of the macro- and microvascular complications of diabetes mellitus. (C) 2002 by the National Kidney Foundation, Inc.

  DOI：

  10.1053/ajkd.2002.30549

文献信息

• The Structures of the Triterpenes Friedelin and Cerin^1,2
  作者：E. J. Corey、J. J. Ursprung

  DOI：10.1021/ja01600a064

  日期：1956.10
• <b>Synthesis of a β-Amyrin Derivative, Olean-11,12;13,18-diene</b>
  作者：E. J. Corey、Hans-Jurgen. Hess、Stephen. Proskow

  DOI：10.1021/ja00907a016

  日期：1963.12
• TOTAL SYNTHESIS OF A β-AMYRIN DERIVATIVE₂ OLEAN-11,12;13,18-DIENE (V)
  作者：E. J. Corey、Hans-Jürgen Hess、S. Proskow

  DOI：10.1021/ja01528a057

  日期：1959.10
• Brownlie et al., Journal of the Chemical Society, 1956, p. 1377,1380
  作者：Brownlie et al.

  DOI：——

  日期：——
• Takeda, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1943, vol. 63, p. 197,202
  作者：Takeda

  DOI：——

  日期：——